Indication
Treatment of non-segmental vitiligo (NSV) with facial involvement in adults and adolescents from 12 years of age.
Medicine details
- Medicine name:
- ruxolitinib topical (Opzelura)
- SMC ID:
- SMC2960
- Pharmaceutical company
- Incyte Biosciences UK Ltd
- BNF chapter
- Skin
- Submission type
- Resubmission
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC